Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: Cigna (CI), Eli Lilly & Co (LLY)

Tipranks - Tipranks - Tue Apr 7, 5:22AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cigna (CI), Eli Lilly & Co (LLY) and McKesson (MCK) with bullish sentiments.

Easter Sale - 70% Off TipRanks

Cigna (CI)

Bank of America Securities analyst Joanna Gajuk maintained a Buy rating on Cigna today and set a price target of $378.00. The company’s shares closed last Thursday at $270.02, close to its 52-week low of $262.03.

According to TipRanks.com, Gajuk is a 2-star analyst with an average return of 0.7% and a 52.2% success rate. Gajuk covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Brookdale Senior Living. ;'>

Currently, the analyst consensus on Cigna is a Strong Buy with an average price target of $342.62, implying a 28.1% upside from current levels. In a report issued on March 30, Bernstein also maintained a Buy rating on the stock with a $358.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Eli Lilly & Co (LLY)

In a report issued on April 3, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co, with a price target of $1300.00. The company’s shares closed last Thursday at $935.58, close to its 52-week high of $972.53.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 19.4% and a 84.1% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1249.83 average price target, a 32.3% upside from current levels. In a report issued on March 20, TipRanks – xAI also upgraded the stock to Buy with a $1019.00 price target.

McKesson (MCK)

Bank of America Securities analyst Allen Lutz reiterated a Buy rating on McKesson today and set a price target of $1000.00. The company’s shares closed last Thursday at $884.28.

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 11.8% and a 63.1% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Envista Holdings, and Cardinal Health. ;'>

Currently, the analyst consensus on McKesson is a Strong Buy with an average price target of $986.78.

Read More on CI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).